122 related articles for article (PubMed ID: 35647751)
1. [Place of stereotactic radiotherapy in oligoprogressive non-small cell lung cancer].
Bernard G; Klausner G; Blais E; Canova CH; Bourhis J; Troussier I
Rev Med Suisse; 2022 Jun; 18(784):1125-1133. PubMed ID: 35647751
[TBL] [Abstract][Full Text] [Related]
2. SBRT for oligoprogressive oncogene addicted NSCLC.
Basler L; Kroeze SG; Guckenberger M
Lung Cancer; 2017 Apr; 106():50-57. PubMed ID: 28285694
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoints Inhibitors and SRS/SBRT Synergy in Metastatic Non-Small-Cell Lung Cancer and Melanoma: A Systematic Review.
Rodríguez Plá M; Dualde Beltrán D; Ferrer Albiach E
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769050
[No Abstract] [Full Text] [Related]
4. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review.
Chicas-Sett R; Morales-Orue I; Castilla-Martinez J; Zafra-Martin J; Kannemann A; Blanco J; Lloret M; Lara PC
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31052488
[No Abstract] [Full Text] [Related]
5. The Emerging Role of Radiotherapy in Oligoprogressive Non-Small Cell Lung Cancer.
Tam A; Eustace N; Kassardjian A; West H; Williams TM; Amini A
Surg Oncol Clin N Am; 2023 Jul; 32(3):497-514. PubMed ID: 37182989
[TBL] [Abstract][Full Text] [Related]
6. Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer.
Campo M; Al-Halabi H; Khandekar M; Shaw AT; Sequist LV; Willers H
Oncologist; 2016 Aug; 21(8):964-73. PubMed ID: 27354669
[TBL] [Abstract][Full Text] [Related]
7. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
8. Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone?
Tang X; Shen Y; Meng Y; Hou L; Zhou C; Yu C; Jia H; Wang W; Ren G; Cai J; Li XA; Yang H; Kong FS
Ann Palliat Med; 2021 Mar; 10(3):2832-2842. PubMed ID: 33548998
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching.
Dong B; Wang J; Zhu X; Chen Y; Xu Y; Shao K; Zheng L; Ying H; Chen M; Cao J
Radiat Oncol; 2019 Nov; 14(1):195. PubMed ID: 31699115
[TBL] [Abstract][Full Text] [Related]
10. SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.
Chen Y; Gao M; Huang Z; Yu J; Meng X
J Hematol Oncol; 2020 Jul; 13(1):105. PubMed ID: 32723363
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.
Ouyang W; Yu J; Nuerjiang S; Li Z; Wang D; Wang X; Zhang J; Xie C
Cancer Med; 2019 Aug; 8(10):4605-4614. PubMed ID: 31245933
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of SBRT for lung oligo-recurrence of non-small cell lung cancer: a retrospective analysis.
Lin Q; Zhou N; Zhu X; Lin J; Fang J; Gu F; Sun X; Wang Y
J Radiat Res; 2022 Mar; 63(2):272-280. PubMed ID: 34958672
[TBL] [Abstract][Full Text] [Related]
13. 30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease.
Osti MF; Agolli L; Valeriani M; Reverberi C; Bracci S; Marinelli L; De Sanctis V; Cortesi E; Martelli M; De Dominicis C; Minniti G; Nicosia L
Lung Cancer; 2018 Aug; 122():165-170. PubMed ID: 30032826
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis.
Rusthoven KE; Hammerman SF; Kavanagh BD; Birtwhistle MJ; Stares M; Camidge DR
Acta Oncol; 2009; 48(4):578-83. PubMed ID: 19373699
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Kann BH; Miccio JA; Stahl JM; Ross R; Verma V; Dosoretz AP; Park HS; Shafman TD; Gross CP; Yu JB; Decker RH
Radiother Oncol; 2019 Mar; 132():188-196. PubMed ID: 30391106
[TBL] [Abstract][Full Text] [Related]
17. Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?
Merino Lara T; Helou J; Poon I; Sahgal A; Chung HT; Chu W; Soliman H; Ung Y; Verma S; Cheema P; Cheng S; Khanna S; Erler D; Zhang L; Cheung P
Lung Cancer; 2018 Oct; 124():219-226. PubMed ID: 30268464
[TBL] [Abstract][Full Text] [Related]
18. The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
Franceschini D; De Rose F; Cozzi S; Franzese C; Rossi S; Finocchiaro G; Toschi L; Santoro A; Scorsetti M
Crit Rev Oncol Hematol; 2020 Apr; 148():102894. PubMed ID: 32062314
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of stereotactic radiotherapy for lung lesions and conventional radiotherapy for nodal areas in primary lung malignancies.
Kim YJ; Kim SS; Song SY; Choi EK
Radiat Oncol; 2018 Jul; 13(1):127. PubMed ID: 29996863
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiotherapy (SBRT) for Stage I lung cancer.
Nagata Y; Kimura T
Jpn J Clin Oncol; 2018 May; 48(5):405-409. PubMed ID: 29635536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
